Drugs / Peresolimab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05959109 | Jul 2023 → Jan 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05440136 | Jun 2022 → Mar 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04152382 | Nov 2019 → Feb 2022 | psoriasis | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT03715192 | Dec 2018 → Dec 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT05516758 | Aug 2022 → Nov 2023 | rheumatoid arthritis | Eli Lilly and Company | Terminated | Met primary |
| Phase 2 | NCT04634253 | Jan 2021 → Jan 2022 | rheumatoid arthritis | Eli Lilly and Company | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-18 | Eli Lilly and Company | Results Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine lilly.com ↗
These data represent the first clinical evidence that stimulating the endogenous PD-1 inhibitory pathway could be an effective approach to treat rheumatologic disease. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-05-18 | Eli Lilly and Company | Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine lilly.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peresolimab | “Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway.” PMID 37195941 ↗ May 2023 |
| Known as | LY3462817 | “A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis” NCT05516758 ↗ |
| Action | Activate | “designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway” PMID 37195941 ↗ May 2023 |
| Modality | Monoclonal antibody | “Peresolimab is a humanized IgG1 monoclonal antibody” PMID 37195941 ↗ May 2023 |
| Route | Intravenous | “Administered IV” NCT03715192 ↗ |